Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology
From MaRDI portal
Publication:3078865
DOI10.1111/j.0006-341X.2001.01089.xzbMath1209.62332WikidataQ40669546 ScholiaQ40669546MaRDI QIDQ3078865
Nigel Stallard, Peter F. Thall
Publication date: 1 March 2011
Published in: Biometrics (Search for Journal in Brave)
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10) Medical applications (general) (92C50)
Related Items (2)
Decision‐theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta‐binomial distribution ⋮ Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies
Cites Work
- One-Sample Multiple Testing Procedure for Phase II Clinical Trials
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
- An Optimal Design for Screening Trials
- Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
- Bayesian Monitoring of Event Rates with Censored Data
- Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
This page was built for publication: Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology
